Effect of Lipin administration in a comprehensive treatment of community-acquired pneumonia associated with COVID-19

dc.contributor.author	Novychenko, Yuliia
dc.contributor.author	Khukhlina, Oksana
dc.contributor.author	Kovalenko, Svitlana
dc.contributor.author	Dudka, Inna
dc.date.accessioned	2024-11-13T11:53:17Z
dc.date.available	2024-11-13T11:53:17Z
dc.date.issued	2021
dc.identifier.uri	http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/25921
dc.description.abstract	Abstract. The article describes the experience of practical use of Ukrainian drug Lipin (phosphatidylcholine (lecithin)) for the treatment of patients with pneumonias associated with COVID-19. The drug does not have any analogues at the market of phosphatidylcholines, possesses a strong anti-hypoxic action, promotes oxygen diffusion rate from the lungs into the blood and from the blood to the tissues, normalizes the processes of tissue respiration, restores functional activity of the endothelial cells, and improves microcirculation and rheological blood properties.	uk_UA
dc.language.iso	en	uk_UA
dc.publisher	PharmacologyOnLine (міжнародний онлайн-журнал)	uk_UA
dc.subject	pneumonia	uk_UA
dc.subject	COVID-19	uk_UA
dc.subject	treatment	uk_UA
dc.subject	phosphatidylcholine	uk_UA
dc.title	Effect of Lipin administration in a comprehensive treatment of community-acquired pneumonia associated with COVID-19	uk_UA
dc.type	Article	uk_UA